PD-1 drugs for Head and Neck Squamous Cell Carcinoma
3 tracked PD-1 drugs in the Head and Neck Squamous Cell Carcinoma race. The class explanation lives on the PD-1 page; the full indication pipeline across every mechanism is on the Head and Neck Squamous Cell Carcinoma page.
3 approved / phase 4
Head-to-head evidence: Nivolumab vs Opdivo Qvantig · Nivolumab vs Pembrolizumab · Opdivo Qvantig vs Pembrolizumab